AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that target and degrade disease-related proteins. Our mission is to develop new class of drugs BIGPRO® (Bi-functional liGand induced PROteolysis) under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases. We focus on novel therapies for cancer, neurodegeneration, and aging diseases. We are turning innovation into new therapeutics – new opportunities to target difficult-to-treat diseases and diseases plagued by drug resistance.